EGRX Eagle Pharmaceuticals Inc.

+0.7  (+1%)
Previous Close 47.11
Open 47.16
Price To Book 4.14
Market Cap 665720592
Shares 13,924,296
Volume 237,272
Short Ratio
Av. Daily Volume 208,755

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Pivotal trial data released October 30, 2018 did not meet primary endpoints.
Breast cancer
Tentative approval announced October 27, 2017. Full approval pending patent litigation with Eli Lilly.
Nonsquamous Non-Small Cell Lung Cancer (NSCLC) and Mesothelioma
CRL issued July 26, 2017. Additional trial required.
Exertional heat stroke (EHS)
Tentative approval July 2 2014. Teva has also received orphan drug and related pediatric exclusivity expiring in September 2015 and May 2016 for the CLL and NHL indications, respectively.
EP-3101 (bendamustine RTD)
Chronic lymphocytic leukemia; Indolent non-Hodgkin's lymphoma - cancer
CRL March 18 2016. FDA requested further characterization of bivalirudin-related substances in the drug product
KANGIO (bivalirudin injection)
Percutaneous Coronary Intervention (PCI) and Percutaneous Transluminal Coronary Angioplasty (PTCA)
Approved December 24, 2015.
Docetaxel Injection
Breast, non-small cell lung, prostate gastric adenocarcinoma, and head and neck cancer
Approved July 22, 2014 under priority review.
Malignant hyperthermia - cancer
Phase 2 trial ongoing.
MDMA/meth intoxication
Phase 3 completion of enrollment announced August 30, 2018.
Exertional heat stroke (EHS)

Latest News

  1. Eagle Pharmaceuticals, Inc. Expands Licensing Agreement for BENDEKA™ with Teva Pharmaceuticals International GmbH
  2. See what the IHS Markit Score report has to say about Eagle Pharmaceuticals Inc.
  3. Don't Sell Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) Before You Read This
  4. Consolidated Research: 2019 Summary Expectations for Penn National Gaming, Nomad Foods, Americold Realty Trust, Cboe Global Markets, Eagle Pharmaceuticals, and National Commerce — Fundamental Analysis, Key Performance Indications
  5. Edited Transcript of EGRX earnings conference call or presentation 28-Feb-19 1:30pm GMT
  6. Eagle Pharmaceuticals Inc (EGRX) Q4 2018 Earnings Conference Call Transcript
  7. Eagle Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2018 Results
  8. Eagle Pharmaceuticals, Inc. to Host Earnings Call
  9. Is Eagle Pharmaceuticals, Inc.’s (NASDAQ:EGRX) ROE Of 15% Impressive?
  10. Analysts Estimate Eagle Pharmaceuticals (EGRX) to Report a Decline in Earnings: What to Look Out for
  11. Eagle Pharmaceuticals to Discuss Fourth Quarter and Full Year 2018 Financial Results on February 28, 2019
  12. Earnings Preview: Eagle Pharmaceuticals (EGRX) Q4 Earnings Expected to Decline
  13. Should Value Investors Buy Eagle Pharmaceuticals (EGRX) Stock?
  14. Does Eagle Pharmaceuticals, Inc.’s (NASDAQ:EGRX) CEO Pay Matter?
  15. Eagle Pharmaceuticals, Inc. to Present at 37th Annual J.P. Morgan Healthcare Conference